AGM Trading Statement

Ahead of its Annual General Meeting later today, Spire Healthcare Group plc (LSE: SPI), a leading independent healthcare group in the UK, issues the following trading statement for the period 1 January 2025 to 30 April 2025 ("the period").

The Board is pleased to confirm that performance in the period has been in line with our expectations and the 2025 guidance provided. Furthermore, our on-going transformation programme, which is expected to deliver at least £30m in efficiencies during FY25, remains on track with benefits weighted towards the second half of the year.

We confirm, as a business with 100% direct UK revenue exposure, we do not currently anticipate any material cost or supply chain impacts as a result of recent tariff announcements.

Spire has also been recently named a founding supplier as part of the Government's National Strategic Supplier Relationship programme. We look forward to working with the NHS to build a strong, long term and sustainable footing for increased NHS commissioning.

Upcoming events

Primary Care roundtable 20 May: Investor and analyst event, hosted by our Primary Care Executive Management Team. Taking place on 20 May at 9am as a hybrid event. To attend in-person please contact investors@spirehealthcare.com or for those who wish to join virtually please register using the following link and webinar ID 812 2509 3179:

Notice of interim results 31 July: results for the six-month period ending 30 June 2025 will be announced on Thursday, 31 July 2025. A link to the webcast will be provided in due course through our website at https://www.investors.spirehealthcare.com